Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXFP1 | Q9HBX9 | 6/20 | 0.58 |
| ▸ | GRIK1 | P39086 | 2/20 | 0.57 |
| ▸ | MAPT | P10636 | 2/20 | 0.56 |
| ▸ | MEN1 | O00255 | 2/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.56 |
| ▸ | HTT | P42858 | 1/20 | 0.56 |
| ▸ | RAB9A | P51151 | 1/20 | 0.56 |
| ▸ | MTOR | P42345 | 1/20 | 0.56 |
| ▸ | MPO | P05164 | 1/20 | 0.54 |
| ▸ | IDH1 | O75874 | 1/20 | 0.53 |
| ▸ | KDR | P35968 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | KCNK3 | O14649 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17664369 | 0.90 | MAPT (0.61) | RXFP1GRIK1MAPTMEN1KMT2A | |
| SCHEMBL17664282 | 0.88 | MEN1 (0.70) | RXFP1GRIK1MAPTMEN1KMT2A | |
| SCHEMBL17664268 | 0.87 | RXFP1 (0.57) | RXFP1GRIK1MAPTMEN1KMT2A | |
| SCHEMBL17664284 | 0.87 | GRIK1 (0.61) | RXFP1GRIK1MAPTMEN1KMT2A | |
| SCHEMBL17664366 | 0.87 | GRIK1 (0.58) | RXFP1GRIK1MAPTMEN1KMT2A | |
| SCHEMBL17664285 | 0.86 | GRIK1 (0.64) | RXFP1GRIK1MAPTMEN1KMT2A | |
| SCHEMBL17664277 | 0.86 | MAPT (0.59) | GRIK1MAPTMEN1KMT2AHTT | |
| SCHEMBL5313393 | 0.85 | MAPT (0.75) | RXFP1MAPTMEN1KMT2AHTT | |
| SCHEMBL30447521 | 0.85 | MAPT (0.75) | RXFP1MAPTMEN1KMT2AHTT | |
| SCHEMBL17664309 | 0.84 | P2RX1 (0.60) | RXFP1GRIK1MAPTMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170273922-A1 | UREA AND BIS-UREA BASED COMPOUNDS AND ANALOGUES THEREOF USEFUL IN THE TREATMENT OF ANDROGEN RECEPTOR MEDIATED DISEASES OR DISORDERS | THE ROYAL INSTITUTION FOR THE ADVANCEMENT OF LEARNING/MCGILL UNIVERSITY (CA) | 2017-09-28 | — | — | US | disclosed |
| WO-2016049774-A1 | UREA AND BIS-UREA BASED COMPOUNDS AND ANALOGUES THEREOF USEFUL IN THE TREATMENT OF ANDROGEN RECEPTOR MEDIATED DISEASES OR DISORDERS | THE ROYAL INSTITUTION FOR THE ADVANCEMENT OF LEARNING/MCGILL UNIVERSITY (CA) | 2016-04-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170273922-A1 | UREA AND BIS-UREA BASED COMPOUNDS AND ANALOGUES THEREOF USEFUL IN THE TREATMENT OF ANDROGEN RECEPTOR MEDIATED DISEASES OR DISORDERS | AR, UTS2R, SHBG | RXFP1 2061/4885GRIK1 3740/4885MAPT 367/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.